• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Mainz Biomed N.V.

    11/26/25 5:00:11 PM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MYNZ alert in real time by email
    6-K 1 ea0266986-6k_mainz.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of November 2025

     

    Commission File No. 001-41010

     

    MAINZ BIOMED N.V.

    (Translation of registrant’s name into English)

     

    Robert Koch Strasse 50
    55129 Mainz
    Germany

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

     

    Form 20-F ☒     Form 40-F ☐

     

     

     

     

     

     

    Deed of Amendment

     

    On November 13, 2025, we amended our Articles of Amendment by a Deed of Amendment. Among the primary changes to our Articles of Amendment were to:

     

    ●decrease the nominal value of our nominal value of our ordinary shares and preferred shares from €0.40 to €0.01;

     

    ●increase our authorized share capital to €125,000 divided into (i) 11,250,000 ordinary shares and 1,250,000 preferred shares (which will be increased into an authorized share capital of €500,000 divided into (i) 45,000,000 ordinary shares and (ii) 5,000,000 preferred shares if the number of outstanding ordinary shares exceeds 10,000,000); and

     

    ●eliminate the ability to issue fractional shares.

     

    The above description is qualified in its entirety by reference to the complete text of the English language translation of the Deed of Amendment attached as Exhibit 4.1 to this report, to our Articles of Association, as amended.

     

    Exhibit Index

     

    Exhibit No.   Description
         
    4.1   Unofficial English translation of Deed of Amendment, dated November 13, 2025

     

    The information contained in this Report on Form 6-K is hereby incorporated by reference into our Registration Statement on Form F-3 (File No. 333-269091) and into the base prospectus and any prospectus supplement outstanding under the foregoing registration statement.

     

    1

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: November 26, 2025 By: /s/ William J. Caragol
        Chief Financial Officer

     

    2

     

    Get the next $MYNZ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MYNZ

    DatePrice TargetRatingAnalyst
    2/14/2025$14.00Buy
    Maxim Group
    11/25/2024Buy → Neutral
    H.C. Wainwright
    11/21/2023Overweight → Neutral
    Cantor Fitzgerald
    6/21/2022$25.00Buy
    H.C. Wainwright
    More analyst ratings

    $MYNZ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    DoctorBox Adds Mainz Biomed's ColoAlert(R) to Its Portfolio

    BERKELEY, Calif. and MAINZ, Germany, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), molecular genetics diagnostic company specializing in the early detection of cancer, today announced that its test ColoAlert® has been added to the portfolio of DoctorBox, one of Germany's leading pioneers in digital health. This marks another important milestone in Mainz Biomed's European growth strategy and highlights the increasing importance of innovative, personalized solutions in preventive medicine. Laboratory analysis will be performed by Mainz Biomed's long-standing partner, the European Oncology Lab, led by Dr. med. Annette Buhlmann in St. Ingb

    12/2/25 8:01:00 AM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mainz Biomed and OncoVanguard8 Enter into Agreement to bring ColoAlert to South America

    BERKELEY, Calif. and MAINZ, Germany, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced the signing of a Memorandum of Understanding ("MOU") with OncoVanguard8, a distributor of oncological innovations. The collaboration aims to introduce ColoAlert®, a DNA-based colorectal cancer (CRC) screening test, to South America, starting with Peru. Colorectal cancer continues to represent one of the most prevalent yet largely preventable cancer types on a global scale. In the three initial launch markets Peru, Colombia and Ecuador alone, approximat

    11/18/25 8:01:00 AM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025

    BERKELEY, Calif. and MAINZ, Germany, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce its participation in MEDICA 2025, one of the world's leading healthcare trade shows, taking place from 17–20 November, 2025, in Düsseldorf, Germany. With over 5,000 exhibitors from 70 countries and 80,000 visitors expected, MEDICA continues to serve as a pioneering international platform for innovation, communication, and business development across the entire medical technology value chain. The event consistently sets trends for the future of g

    11/12/25 8:01:00 AM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MYNZ
    SEC Filings

    View All

    SEC Form F-3 filed by Mainz Biomed N.V.

    F-3 - MAINZ BIOMED N.V. (0001874252) (Filer)

    12/5/25 5:00:50 PM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Mainz Biomed N.V.

    424B5 - MAINZ BIOMED N.V. (0001874252) (Filer)

    11/26/25 5:02:45 PM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Mainz Biomed N.V.

    6-K - MAINZ BIOMED N.V. (0001874252) (Filer)

    11/26/25 5:00:11 PM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MYNZ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on Mainz Biomed B.V. with a new price target

    Maxim Group initiated coverage of Mainz Biomed B.V. with a rating of Buy and set a new price target of $14.00

    2/14/25 8:10:14 AM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mainz Biomed B.V. downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Mainz Biomed B.V. from Buy to Neutral

    11/25/24 7:48:30 AM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mainz Biomed B.V. downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded Mainz Biomed B.V. from Overweight to Neutral

    11/21/23 7:33:52 AM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MYNZ
    Leadership Updates

    Live Leadership Updates

    View All

    Mainz Biomed to Present the Future of Colorectal Cancer Screening at WEO CRC Screening Committee Meeting

    BERKELEY, Calif. and MAINZ, Germany, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, is pleased to announce its participation in the upcoming Colorectal Cancer (CRC) Screening Committee Plenary Meeting and Expert Working Group (EWG) Sessions hosted by the World Endoscopy Organization (WEO), taking place on October 3rd, 2025, in Berlin, Germany. This high-level gathering brings together global leaders in colorectal cancer screening to evaluate emerging technologies, exchange scientific insights, and help shape future strategies for early detection

    9/30/25 8:01:00 AM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mainz Biomed Enters into Technology Partnership with EDX Medical Group

    BERKELEY, Calif. and MAINZ, Germany, April 29, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, has entered into a technology partnership with UK-based EDX Medical Group plc (AQSE: EDX), which develops innovative digital diagnostic products and services supporting personalized treatments for cancer, cardiovascular and infectious diseases. Under the agreement, EDX Medical will access Mainz Biomed's molecular diagnostic technology as part of the expansion of its portfolio of products for sale in the UK. "We are delighted to join forces with EDX Medical Limited t

    4/29/25 8:01:00 AM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador

    BERKELEY, Calif. and MAINZ, Germany, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the addition of Petra Smeltzer Starke as a Brand Ambassador for the Company. As Brand Ambassador she will help the Company in the development and dissemination of messaging focused on the importance of early detection of colorectal cancer. "We are excited about Petra joining our team as Brand Ambassador. Her broad and deep experience will be invaluable to us as we bring our next generation colorectal cancer screening product to market, with the

    9/18/24 8:01:00 AM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MYNZ
    Financials

    Live finance-specific insights

    View All

    Mainz Biomed Acquires Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program

    Transaction entails executing option agreements to purchase IP portfolio associated with current ColoAlert product and the novel gene expression (mRNA) biomarkers being evaluated in ColoFuture/eAARLY DETECT Studies BERKELEY, Calif. and MAINZ, Germany, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the execution of its option from Uni Targeting Research AS to acquire all of the previously licensed scientific intellectual property ("IP") for its flagship product ColoAlert, a highly efficacious, and easy-to-use detection test for colorec

    2/21/23 3:01:00 AM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mainz Biomed Acquires Exclusive Rights to Novel mRNA Biomarkers

    Potential for ColoAlert to Emerge as the Most Robust and Accurate At-home Screening Test for Colorectal Cancer Biomarkers Demonstrated Unique Ability to Identify Curable Precancerous Colonic Polyps as well as Curable Early-Stage Colorectal Cancer BERKELEY, Calif. and MAINZ, Germany, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today it has entered into a Technology Rights Agreement with Socpra Sciences Santé Et Humaines S.E.C. ("TTS") to access a portfolio of novel mRNA biomarkers for potential future integration into ColoAlert,

    1/5/22 3:01:00 AM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MYNZ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mainz Biomed N.V.

    SC 13G/A - MAINZ BIOMED N.V. (0001874252) (Subject)

    10/7/24 4:47:27 PM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Mainz Biomed N.V. (Amendment)

    SC 13G/A - MAINZ BIOMED N.V. (0001874252) (Subject)

    2/13/24 2:39:04 PM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Mainz Biomed N.V.

    SC 13G - MAINZ BIOMED N.V. (0001874252) (Subject)

    3/1/23 6:38:43 AM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care